ArticleChemMedChem2026
Discovery of a 4'-Azido Fleximer Nucleoside Analog With Broad-Spectrum Antiviral Activity Against DENV, EBOV, and Other RNA Viruses.
Kyle A Davis, Ryan L Slack, Thomas R Foulkes, Tereza Frčková, Lenka Tomková, Jessica L Smith, Meareg Amare, Grayson D Pipher, Peter Halfmann, Alec J Hirsch and 3 more
Abstract read
In one paragraphArticle in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Thomas R FoulkesDepartment of Chemistry and Biochemistry, University of Maryland Baltimore County, Baltimore, Maryland, USA.
Tereza FrčkováLaboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.
Lenka TomkováLaboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.
Jessica L SmithVaccine and Gene Therapy Institute, Oregon Health and Sciences University, Beaverton, Oregon, USA.
Meareg AmareInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Peter HalfmannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID https://orcid.org/0000-0002-1648-1625 Alec J HirschVaccine and Gene Therapy Institute, Oregon Health and Sciences University, Beaverton, Oregon, USA.
Stefan G SarafianosCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-5840-154X Funding
Research Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S · 2022 to 2022
$65.5MUniversity of Maryland BaltImore Life Science Discovery (UM-BILD) AcceleratorU01GM152511 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI Jason J Rose, KARL V. STEINER · 2023 to 2026
$4.0MGraduate Training at The Chemistry Biology InterfaceT32GM158458 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI Steven Fletcher, Aaron T Smith · 2025 to 2026
$564kMinistry of Education, Youth and Sports of the Czech Republic within the INTER-EXCELLENCE II program and the INTER-ACTION subprogram LUAUS25011NIAID NIH HHS U19 AI171292NIGMS NIH HHS T32 GM158458NIGMS NIH HHS U01 GM152511NIH HHS 5U01GM152511NIH HHS GM158458NIH HHS U19 AI1271292UMBC Technology Catalyst Fund
6 · The paper itselfAbstract
The ongoing emergence and reemergence of RNA viruses from multiple viral families highlights the urgent need for broad-spectrum antiviral therapeutics. To address this issue, a series of 4'-azido fleximer nucleoside analogs were synthesized and evaluated for broad-spectrum antiviral activity against pathogens of epidemic/pandemic concern. One compound, KAD-039, featuring a 2', 3'-diisobutyrate-5'-ProTide prodrug, exhibited potent antiviral activity across flaviviruses, filoviruses, and coronaviruses, with EC
Indexed as
Antiviral AgentsDengue VirusDrug DiscoveryNucleosidesRNA VirusesAnimalsDogsDose-Response Relationship, DrugHumansMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntiviral AgentsNucleosidesantiviralbroad‐spectrumfleximernucleosideproTide
Identifiers
PMID42675541
PMCPMC13530309
What OpenQuestion holds
Textmetadata
Read underepoch 390